At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CELZ Creative Medical Technology Holdings, Inc.
Post-Mkt 03-20 17:06:13 EDT
1.84
-0.04
-2.13%
盘后1.88
+0.04+2.17%
16:02 EDT
High1.88Low1.81Vol47.90K
Open1.88D1 Closing1.88Amplitude3.96%
Mkt Cap6.43MTradable Cap5.94MTotal Shares3.49M
T/O88.29KT/O Rate1.48%Tradable Shares3.23M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Creative Medical Technology FY 2025 net loss rises 9% to USD 6 million on revenue down 46% to USD 6,000
Reuters  ·  20 minutes ago
Creative Medical Technology FY 2025 net loss rises 9% to USD 6 million on revenue down 46% to USD 6,000
Creative Medical Technology Holdings Inc expected to post a loss of 37 cents a share - Earnings Preview
Reuters  ·  03-11
Creative Medical Technology Holdings Inc expected to post a loss of 37 cents a share - Earnings Preview
BRIEF-Creative Medical Technology Holdings Achieves Second Who Inn Milestone
Reuters  ·  02-10
BRIEF-Creative Medical Technology Holdings Achieves Second Who Inn Milestone
Creative Medical Technology Holdings Achieves Second Who Inn Milestone, Strengthening Global Regulatory Positioning Across Expanding Cell Therapy Pipeline
THOMSON REUTERS  ·  02-10
Creative Medical Technology Holdings Achieves Second Who Inn Milestone, Strengthening Global Regulatory Positioning Across Expanding Cell Therapy Pipeline
Creative Medical Technology Holdings Achieves Second WHO INN Milestone for Cell Therapy Pipeline
Reuters  ·  02-10
Creative Medical Technology Holdings Achieves Second WHO INN Milestone for Cell Therapy Pipeline
Creative Medical Technology Reports Positive Interim Results for CELZ-201 in Chronic Lower Back Pain Trial
Reuters  ·  01-13
Creative Medical Technology Reports Positive Interim Results for CELZ-201 in Chronic Lower Back Pain Trial
Creative Medical Technology Holdings Reaches Major Clinical Inflection Point With Positive Interim Data From Adapt Trial and Celz-201 (Olastrocel) in the Treatment of Chronic Lower Back Pain
THOMSON REUTERS  ·  01-13
Creative Medical Technology Holdings Reaches Major Clinical Inflection Point With Positive Interim Data From Adapt Trial and Celz-201 (Olastrocel) in the Treatment of Chronic Lower Back Pain
Creative Medical Technology Holdings Secures Regulatory Approval for Burn Pit Initiative
Reuters  ·  01-06
Creative Medical Technology Holdings Secures Regulatory Approval for Burn Pit Initiative
Creative Medical Technology Holdings Inc. Held Annual Shareholder Meeting
Reuters  ·  2025-12-20
Creative Medical Technology Holdings Inc. Held Annual Shareholder Meeting
BRIEF-Creative Medical Technology Completes Enrollment In FDA-Cleared Adapt Trial
Reuters  ·  2025-12-17
BRIEF-Creative Medical Technology Completes Enrollment In FDA-Cleared Adapt Trial
Creative Medical Technology Holdings Completes Enrollment in FDA-Cleared CELZ-201 Trial
Reuters  ·  2025-12-17
Creative Medical Technology Holdings Completes Enrollment in FDA-Cleared CELZ-201 Trial
Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared Adapt Trial for Celz-201-Olastrocel, Marking Major Clinical Inflection Point
THOMSON REUTERS  ·  2025-12-17
Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared Adapt Trial for Celz-201-Olastrocel, Marking Major Clinical Inflection Point
BRIEF-Creative Medical Technology Holdings Announces World Health Organization Approval Of “Olastrocel”
Reuters  ·  2025-12-02
BRIEF-Creative Medical Technology Holdings Announces World Health Organization Approval Of “Olastrocel”
Creative Medical Technology Holdings Announces World Health Organization Approval of “Olastrocel” as Inn for Lead Allogeneic Cell Therapy Celz-201
THOMSON REUTERS  ·  2025-12-02
Creative Medical Technology Holdings Announces World Health Organization Approval of “Olastrocel” as Inn for Lead Allogeneic Cell Therapy Celz-201
Creative Medical Technology Holdings Awards CEO $100,000 Bonus and CFO $25,000 Bonus
Reuters  ·  2025-11-12
Creative Medical Technology Holdings Awards CEO $100,000 Bonus and CFO $25,000 Bonus
Creative Medical Technology Holdings Inc expected to post a loss of 48 cents a share - Earnings Preview
Reuters  ·  2025-11-05
Creative Medical Technology Holdings Inc expected to post a loss of 48 cents a share - Earnings Preview
Creative Medical Technology Holdings Raises $4.2 Million Through Warrant Exercises and Issues New Warrants
Reuters  ·  2025-11-01
Creative Medical Technology Holdings Raises $4.2 Million Through Warrant Exercises and Issues New Warrants
Creative Medical Technology Holdings, Inc. Ignites Next-Gen Regenerative BioDefense Initiative for U.S. Veterans Exposed to Burn Pits
GlobeNewswire  ·  2025-10-30
Creative Medical Technology Holdings, Inc. Ignites Next-Gen Regenerative BioDefense Initiative for U.S. Veterans Exposed to Burn Pits
Creative Medical Technology Holdings Inc. Announces Date for Annual Stockholders Meeting
Reuters  ·  2025-10-30
Creative Medical Technology Holdings Inc. Announces Date for Annual Stockholders Meeting
Creative Medical announces agreements for warrant exercise for $4.2M proceeds
TIPRANKS  ·  2025-10-29
Creative Medical announces agreements for warrant exercise for $4.2M proceeds
No data available

Introduction

Company Name.
Creative Medical Technology Holdings, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
Issue price:
--